This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 04 April 2025; doi:10.1038/s41569-025-01146-x Hearttransplantation remains the optimal long-term treatment for appropriate patients with advanced heartfailure. However, the donor heart shortage is a limiting factor, and the risk profile of transplant candidates is worsening.
IntroductionThe objective of this study was to examine the impact of ventricular assist device support as a bridge to hearttransplantation in children with end-stage heartfailure. Patients were divided into two groups: with pre transplant ventricular assist device (VAD) support and without VAD support.
The risk of early heartfailure after hearttransplantation is lower if the donor heart is stored in a so-called heart-in-a-box instead of in the usual cooler with ice. This is according to a study by researchers at the University of Gothenburg.
(MedPage Today) -- A 54-year-old New Jersey woman has become the first-ever patient to undergo combined mechanical heart pump and gene-edited pig kidney transplant surgery, doctors announced. The patient, Lisa Pisano, had heartfailure and end.
Jon Kobashigawa, MD, of the Smidt Heart Institute at Cedars-Sinai, is an expert in hearttransplantation, heartfailure, and other complex cardiac conditions. Kobashigawa was instrumental in expanding the Comprehensive Transplant Program at Cedars-Sinai , one of the largest transplant programs in the world. “Dr.
The increasing prevalence of heartfailure (HF) has led to advancements in therapeutic strategies, including the development of new pharmacological treatments and the expansion of guideline recommendations across the spectrum of left ventricular ejection fractions.
RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heartfailure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/hearttransplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Atlanta, GA.
based Vanderbilt Transplant Center partnered with Evansville, Ind.-based based Deaconess Health System to open a new transplant clinic in Newburgh, Ind. Nashville, Tenn.-based
Advanced heartfailure (AdvHF) can only be treated definitively by hearttransplantation (HTx), yet problems such right ventricle dysfunction (RVD), rejection, cardiac allograft vasculopathy (CAV), and primary graft dysfunction (PGD) are linked to a poor prognosis.
However, information on its efficacy and safety in patients with heartfailure remains limited. Case presentation A 43-year-old man with a body mass index of 41 kg/m 2 was admitted to our hospital for acute heartfailure due to dilated cardiomyopathy. No adverse events were observed during B-SES.
For his groundbreaking work in gene discovery and identification, growing three different programs as a pediatric cardiology chief and his development of three separate high-level cardiomyopathy, heartfailure (HF) and transplant programs, Towbin received the ACC Lifetime Achievement Award during ACC.25
Pictured Left to Right: Members and students of the McGill Gene Editing Laboratory at The Texas Heart Institute in Houston, Texas: Fansen Meng, PhD, Xiao Li, PhD, James Martin, MD, PhD, Rich Li, PhD (back), Maggie Lim (undergraduate student at Rice University front), Yuka Morikawa, PhD, Ann Bromley.
Early identification of kidney dysfunction in patients with advanced heartfailure is crucial for timely interventions. Circulation, Ahead of Print. Hemodynamic derangements and maladaptive neurohormonal upregulations contribute to fluctuations in kidney indices and electrolytes that may recover with guideline-directed medical therapy.
Despite being a hearttransplantation candidate, she declined revascularization and sought alternative treatments for angina, dyspnea, and daily activity limitations. EECP may alleviate the need for hearttransplantation through its integration as a standard early intervention.
(MedPage Today) -- In a prospective cohort study, hearing loss was associated with incident heartfailure, a relationship partly mediated by psychological distress. Heart) A retrospective analysis from Israel suggested that markers of poor hydration.
The risk of early heartfailure after hearttransplantation is lower if the donor heart is stored in a so-called heart-in-a-box instead of in the usual cooler with ice.
Pediatric hearttransplantation has long been hailed as a life-saving intervention for children suffering from end-stage heartfailure. While the procedure offers hope, the long-term outcomes for these young patients remain suboptimal due to allograft rejection and graft failure.
After struggling with heartfailure for the first months of his life, doctors told his parents that Zeke would need a hearttransplant immediately. Within one day, our hearttransplant team performed the transplant surgery. Now Zane, 6, and Zeke, 5, are living lives the odds said were unlikely.
As the only pediatric hearttransplant program in Louisiana and the only program in the state to offer advanced mechanical support options for pediatric cardiology patients, Ochsner Children’s Hospital is committed to advocating for additional medical devices to enhance its high-quality care to pediatric patients awaiting transplant.
Kittleson, director of HeartFailure Research and director of Post Graduate Medical Education in HeartFailure and Transplantation, is an associate editor specializing in heartfailure. She also has served on the board of directors of the HeartFailure Society of America.
Transplantation is lifesaving for many of our patients. Yet an ongoing challenge is how to expand this opportunity to all patients who need a heart in our current setting of limited resources.
Heartfailure stands as a leading cause of mortality worldwide, demanding advanced treatment options. Despite the urgency for more effective treatments, options for severe heartfailure remain limited.
Extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) devices are well-established adjunctive treatment measures for patients with heartfailure. However, the role of ECMO as a bridge to definitive therapy in a setting of acute heartfailure is less established.
Introduction Hearttransplantation (HT) is the only treatment option in children with heartfailure secondary to cardiomyopathies and non-reparable congenital heart diseases. Rhythm disturbances that develop during follow-up can serve as early indicators of graft rejection and should be carefully evaluated.
The implantation of left ventricular assist devices (LVADs) has been increasing, with good long-term results, in parallel with a growing population with advanced heartfailure (HF). However, in some European countries, LVADs are still underused, with one of the main issues being the patient's late referral.
Racially biased readings of oxygen levels in the blood using pulse oximeters may further limit opportunities for Black patients with heartfailure to receive potentially lifesaving treatments, such as heart pumps and transplants, a Michigan Medicine study finds.
Circulation: HeartFailure, Ahead of Print. Heartfailure is a global disease with significant morbidity. Hearttransplant (HT) can be a lifesaving therapy for select patients with end-stage heartfailure.
There has been a notable increase over the last decade in the volume of outpatient, inpatient, and advanced therapy needs associated with patients with heartfailure (HF),
Ashley Malliett, DMSc, MPAS, PA-C, discusses the importance of timely diagnosis and initiated care, as well as contraindications for transplants and LVAD.
Eosinophilic myocarditis (EM), a rare condition, is fatal if left untreated and has rarely been described in hearttransplant recipients. The cornerstone of treatment is corticosteroids, comprehensive therapy and heartfailure management (including advanced mechanical support for fulminant myocarditis).
When a patient with heartfailure has received a new heart and survives—the transplantation is deemed a success. However, health care overlooks heart recipients who suffer from long-term and often severe symptoms, such as pain and fatigue.
Arrhythmias can lead to cardiac arrest (CA) and heartfailure. When intractable, hearttransplant (HTX) can become the only viable treatment. This rare, high-risk cohort has not been reported as a distinct group.
However, advanced heartfailure therapy never means it can be achieved only by state-of-the-art technology. Cardiac failure management remains basically disciplined medical management and a holistic approach to improve the quality of life. Only few lucky patients end up getting hearttransplantation, the ultimate treatment.
Knowledge and application of European Society of Cardiology/HeartFailure Association (ESC/HFA) guidelines in the management of advanced heartfailure (HF). Respondents were categorized into heartfailure cardiologists (HFCs), general cardiologists (GCs), and other participants (OPs). of HFCs, 19.6%
Heartfailure is a chronic condition that occurs when the heart can no longer operate efficiently on its own, or effectively pump blood throughout the body. Signs of heartfailure may include difficulty breathing, a racing heartbeat/heart palpitations, fatigue, or unexplained swelling.
Early Feasibility Study (FUTURE-HF2) of its FIRE1 System for remote heartfailure monitoring. The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heartfailure.
Dive into the Heart of ACC.24's 24's HeartFailure and Transplant Highlights! 24 sessions in heartfailure and transplant, including trials RELIEVE-HF, REDUCE-AMI, and DanGer Shock. In this podcast, Drs.
Journal of the American Heart Association, Ahead of Print. BackgroundMyocardial fibrosis is prevalent in cardiomyopathies that result in heartfailure with reduced ejection fraction.
Mehra, MD, FRCP described the cutting-edge heart pump and other advances in mechanical circulatory support (MCS) today at the Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) in Prague.
Hearttransplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Patients without CHD were older (mean age 71.5 years) than those with DV-CHD (mean age 59.8 years) and SV-CHD (mean age 17.9
Objective The role of hyperuricaemia as a prognostic maker has been established in chronic heartfailure (HF) but limited information on the association between plasma uric acid (UA) levels and central haemodynamic measurements is available. Conclusions Elevated UA is associated with greater haemodynamic impairment in advanced HF.
Hearttransplantation remains a vital treatment for end-stage heartfailure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need. Addressing this critical barrier could potentially improve post-transplant outcomes and make older donor hearts a viable option.
(MedPage Today) -- To more fairly rank candidates for hearttransplant, researchers developed the U.S. candidate risk score (US-CRS) and found it to better discriminate risk for people with advanced heartfailure than the current six-status system.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content